Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
12/01/2016 12/02/2016 12/05/2016 12/06/2016 12/07/2016 Date
59.6(c) 59.54(c) 58.8(c) 59.06(c) 58.87 Last
431 015 277 527 339 334 245 170 195 445 Volume
-1.81% -0.10% -1.24% +0.44% -0.32% Change
More quotes
Financials (€)
Sales 2016 4 052 M
EBIT 2016 757 M
Net income 2016 467 M
Debt 2016 951 M
Yield 2016 2,06%
Sales 2017 4 342 M
EBIT 2017 911 M
Net income 2017 572 M
Debt 2017 615 M
Yield 2017 2,28%
P/E ratio 2016 22,66
P/E ratio 2017 18,55
EV / Sales2016 3,07x
EV / Sales2017 2,79x
Capitalization 11 488 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
11/17 UCB : Family Epilepsy Scholarship Program Announces 2016 Recipients
11/16 UCB : Juno Biomedical Moving Forward with Regenerative Stroke Treatment
11/15 UCB : The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab peg..
11/11 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU C..
11/03 UCB : Patent Issued for Method for Producing Protein (USPTO 9476081)
10/25 UCB : continues its growth path
10/21 UCB : Transparency notification
10/10 UCB : Transparency notification
10/07 UCB : Transparency notification
10/03 UCB : CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpo..
More news
Sector news : Pharmaceuticals - NEC
04:49p Pharma, biotech stocks fall after Trump comment on drug prices
04:32p MYLAN : EpiPen maker Mylan to restructure and cut its workforce
04:19pDJMARKET SNAPSHOT : Dow, S&P 500 On Track For Records, But Health-care Slumps On T..
02:21pDJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug -- 2nd Updat..
12/06DJNovo Nordisk Pledges to Limit Price Increases in U.S. for Its Drugs
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/13 Late-stage study shows Amgen and UCB's romosozumab significantly increases bo..
09/30 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
07/31 UCB S.A. 2016 Q1 - Results - Earnings Call Slides
07/31 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q2 2016 Results - Earnings Call ..
07/22 Amgen submits BLA in U.S. for osteoporosis candidate romosozumab
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 77,4 €
Spread / Average Target 31%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Mark D. McDade Chief Operating Officer & Executive Vice President
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Loew-Friedrich Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB-28.39%12 312
JOHNSON & JOHNSON9.09%304 863
PFIZER INC.-2.23%191 517
ROCHE HOLDING LTD.-19.65%190 397
NOVARTIS AG-20.79%180 387
MERCK & CO., INC.14.12%166 200
More Results